Table S2 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab

2026 Open access

Read full text
Authors: Miguel F. Sanmamed, Carlos E. de Andrea, David Ruiz-Guillamon, Maria Esperanza Rodriguez-Ruiz, Ignacio Ortego, Iñaki Eguren‐Santamaría, Alberto Benito, Alvaro Lopez-Janeiro, José Gonzalez Gomariz, María Villalba-Esparza, Angie Molina, Anastasia Krasko
+10 more Mariano Ponz‐Sarvisé, Jose M. Lopez-Picazo, Gabriel Gomis, Paula Molero-Glez, Raluca Alexandru, Paulo Perez-Dominguez, Inmaculada Rodríguez, Sandra Sánchez‐Gregorio, José Luiz Pérez-Gracia, Ignacio Melero
DOI: 10.1158/1078-0432.31744652
Cited by: 0

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Immunotherapy and Immune Responses T-cell and B-cell Immunology

Publication details

Publication date
16 March 2026
Language
EN